Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2004

View Archived Issues

A preclinical trial suggests that histamine protects the liver against LPS-induced damage

Therapeutic benefits of Pegasys plus ribavirin in HCV-infected patients

Synthetic truncated PSP94 for metastatic hormone-resistant prostate cancer patients

VaxGen anthrax vaccine candidate prepares to enter phase II trial

Preclinical, preliminary clinical data on GW-280430A, a nondepolarizing neuromuscular blocking agent

Benefits of statins and ACE inhibitors in coronary heart disease

Sinapultide equivalent to poractant alfa in the prevention of RDS

ABI-793 shows promise, complications in renal transplant model

TAK-559, a PPARalpha/gamma coagonist for the treatment of dyslipidemia

Atherosclerosis in LDLR mice inhibited by PPARdelta ligand GW-0742

Novel cytotoxic agent effective against chemotherapy-resistant ovarian carcinoma

Selective acetylcholinesterase inhibitor effective against bladder voiding dysfunction

New data on Fujisawa's histone deacetylase inhibitor FR-901228

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: MacroChem

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Newron

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Munich Biotech

Novel BH3-derived proapoptotic peptides developed by Dana Farber researchers

New IKK inhibitors and their use reported by Aventis Pharma

Novo Nordisk claims the preparation and use of novel PPARdelta agonists

New ORL1 receptor modulators with potential in anxiety and other disorders

CV Therapeutics describes adenosine A3 agonists for cancer and neutropenia therapy

Two series of histamine H4 antagonists prepared and tested at Janssen

Phase III results of R-1549 in ovarian cancer disappoint

European CPMP recommends broader indication for Remicade in early RA

Phase III trial of Tarceva in NSCLC meets endpoints

Genmab licenses GT43 cancer target from Ganymed

CRX-675 enters phase I trial for seasonal allergic rhinitis

ViRexx Medical receives grant to fund phase I trial of Occlusin

Levitra receives Japanese approval

Phase II/III trial of Fibrillex cleared to continue

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...